Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

Conditions:   Relapsed/Refractory Waldenstrom Macroglobulinemia;   Relapsed/Refractory Richter Transformation;   Relapsed/Refractory Burkitt Lymphoma;   Relapsed/Refractory Hairy Cell Leukemia Interventions:   Biological: Brexucabtagene Autoleucel;   Drug: Cyclophosphamide;   Drug: Fludarabine Sponsor:   Kite, A Gilead Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials